References
- Savov E, Trifonova A, Kovachka K, et al. Antimicrobial in vitro activities of ceftazidime-avibactam, meropenem-vaborbactam and plazomicin against multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa - a pilot Bulgarian study. Infect Dis. 2019;51(11–12):870–873.
- Tuon FF, Rocha JL, Formigoni-Pinto MR. Pharmacological aspects and spectrum of action of ceftazidime-avibactam: a systematic review. Infection. 2018;46(2):165–181.
- Rossi F, Cury AP, Franco MRG, et al. The in vitro activity of ceftazidime-avibactam against 417 Gram-negative bacilli collected in 2014 and 2015 at a teaching hospital in Sao Paulo, Brazil. Braz J Infect Dis. 2017;21(5):569–573.
- Tuon FF, Aragao BZ, Santos TA, et al. Acute kidney injury in patients using amikacin in an era of carbapenem-resistant bacteria. Infect Dis. 2016;48(11–12):3.
- Kalluf KO, Arend LN, Wuicik TE, et al. Molecular epidemiology of SPM-1-producing Pseudomonas aeruginosa by rep-PCR in hospitals in Parana, Brazil. Infect Genet Evol. 2017;49:130–133.
- CLSI. Performance standards for antimicrobial susceptibility tests. 30th ed. Wayne (PA): Clinical and Laboratory Standards Institute; 2020.
- Swayne R, Ellington MJ, Curran MD, et al. Utility of a novel multiplex TaqMan PCR assay for metallo-β-lactamase genes plus other TaqMan assays in detecting genes encoding serine carbapenemases and clinically significant extended-spectrum β-lactamases. Int J Antimicrob Agents. 2013;42(4):352–356.
- Rigatto MH, Oliveira MS, Perdigao-Neto LV, et al. Multicenter prospective cohort study of renal failure in patients treated with colistin versus polymyxin B. Antimicrob Agents Chemother. 2016;60(4):2443–2449.
- Tuon FF, Cieslinski J, Rodrigues SDS, et al. Evaluation of in vitro activity of ceftolozane-tazobactam against recent clinical bacterial isolates from Brazil - the EM200 Study. Braz J Infect Dis. 2020;24(2):96–103.
- Pitta RD, Gasparetto J, De Moraes TP, et al. Antimicrobial therapy with aminoglycoside or meropenem in the intensive care unit for hospital associated infections and risk factors for acute kidney injury. Eur J Clin Microbiol Infect Dis. 2020;39(4):723–728.